immunity News and Research

RSS

Novel SARS-CoV-2 spike vaccine candidate produces strong neutralizing response in vivo

A new study by researchers at Mahidol University in Bangkok, Thailand, reports a COVID-19 vaccine candidate called HexaPro in producing neutralizing antibodies against the SARS-CoV-2 spike protein in an animal model.

3 Mar 2021

A model of vaccine-derived herd immunity against COVID-19 in heterogeneous populations

A recent theoretical paper, currently available on the medRxiv preprint server, unveils a novel vaccination model that shows how a herd immunity threshold (HIT) value which considers heterogeneity is substantially lower in comparison with a HIT value of assuming a homogeneous population – with many implications for further vaccination planning.

2 Mar 2021

New nanoparticle-delivered COVID-19 vaccine candidate shows efficacy in ferret model

Researchers from Cleveland Clinic's Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease models.

2 Mar 2021

Ethnic minorities have less access to COVID-19 vaccines, finds study

A new study discusses the results of a survey including well over 1.3 million participants in the UK and the USA. During the initial part of the vaccination campaign – that is, the phase including February 1, 2021 – the researchers found significantly more hesitancy towards the vaccine among Black, Asian, and Hispanic communities, as well as greater difficulty in accessing vaccines among them.

2 Mar 2021

Successful SARS-CoV-2 vaccination hinges on non-pharmaceutical interventions and vaccine deployment strategies

A thought-provoking new study server discusses the factors that determine the successful use of available vaccines to mitigate incidence and mortality rates for COVID-19.

2 Mar 2021

Moderna vaccine reduces viral spread by at least 60 percent, finds study

An interesting new study by researchers at Harvard T.H. Chan School of Public Health in the U.S. suggests that the currently used Moderna vaccine reduces viral shedding by about 60%.

2 Mar 2021

Scientists establish infection models for SARS-CoV-2 UK & South African variants

New research suggests Syrian golden hamsters could be a potentially useful preclinical model for testing vaccine immunity against the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.17 and B.1.351 variant.

1 Mar 2021

Enduring antibody response observed after natural immunity and first Pfizer SARS-CoV-2 vaccine shot

Immunity gained after natural infection from the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is boosted when people take the first Pfizer-BioNTech vaccine, according to a new study led by Iain C. Chapple from the University of Birmingham.

1 Mar 2021

Tier 3 interventions needed to contain SARS-CoV-2 transmission, especially with emergence of variants

Studies have shown that non-pharmaceutical interventions (NPIs) such as social distancing and partial lockdowns effectively contain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. However, because of these measures' huge economic and social cost, the UK introduced a less socially disruptive tier system. This system was aimed at providing a consistent set of control measures with geographic flexibility.

1 Mar 2021

Study: Highly efficient and balanced immune response key to avoiding COVID-19 symptoms

By analyzing blood samples from individuals infected with SARS-CoV-2, researchers in Singapore have begun to unpack the different responses by the body's T cells that determine whether or not an individual develops COVID-19.

1 Mar 2021

Protein kinase inhibitors could help treat immunodeficiency in HIV patients

HIV infections are treated with antiviral drugs which effectively prevent the disease from developing. While pharmacological HIV therapy has advanced considerably, the virus cannot be entirely eliminated from the body with currently available drugs.

1 Mar 2021

Single-dose of BNT162b2 vaccine may not be protective without prior SARS-CoV-2 infection

A new study by researchers at Imperial College London, UK, discusses the effect of a vaccine dose, specifically the BNT162b2 candidate (also known as the ‘Pfizer-BioNTech’ vaccine), on neutralizing antibody titers in individuals who have already been infected with the virus.

1 Mar 2021

One in seven people in England show SARS-CoV-2 antibodies, finds study

The REal-time Assessment of Community Transmission-2 (REACT-2) program completed its fifth round of community surveys in the days between January 26 and February 8, 2021. The findings appear in a new article in the BMJ on February 25, 2021, showing that natural infection and vaccination together account for around 14% seropositivity rates in England at present.

1 Mar 2021

Could SARS-CoV-2 antibody tests before first vaccine dose help increase coverage and protection?

A new study by scientists in the UK raises the very useful hypothesis that natural infection may help spread the vaccine thinner without loss of efficacy.

1 Mar 2021

Study shows how D614G variant gains upper hand over original SARS-CoV-2 virus

Prior to the emergence of new mutants of the coronavirus, such as the British variant B.1.1.7, the SARS-CoV-2 variant named D614G had already mutated from the original SARS-CoV-2 pathogen that triggered the pandemic.

27 Feb 2021

KHN’s ‘What the health?’: Staffing up at HHS

More than a month into President Joe Biden’s term, nominees to fill some of the top posts at the Department of Health and Human Services are finally getting confirmation hearings in the Senate, starting with the nominee for secretary, California Attorney General Xavier Becerra.

26 Feb 2021

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

A new study deals with the clinical and virological effects of circulating SARS-CoV-2 variants, especially as they affect vaccine efficacy.

26 Feb 2021

Structure of SARS-CoV-2 envelope protein-epithelial cell junction protein complex explains virulence

A new study by researchers at Brookhaven National Laboratory and Stony Brook University in the U.S. describes the key interaction between the viral envelope (E) protein and the human cell junction protein, PALS1. The latter is necessary to establish and maintain cell polarity and tight junctions between cells.

26 Feb 2021

Why Astrazeneca and J&J’s vaccines, in use the world over, are still on hold in America

The World Health Organization greenlighted emergency use of AstraZeneca and Oxford's covid-19 vaccine this month, following in the steps of the United Kingdom, the European Union and others, who are already injecting it as quickly as possible into the masses.

26 Feb 2021

What is the impact of demographics and air quality on COVID-19 mortality?

A new piece of research was conducted using a wide range of variables related to demographic and environmental factors in New York State (NYS), USA. NYS consists of urban and ethnically diverse counties, some of which are population-dense while others are population-sparse.

26 Feb 2021

immunity News and Research

Novel SARS-CoV-2 spike vaccine candidate produces strong neutralizing response in vivo

A model of vaccine-derived herd immunity against COVID-19 in heterogeneous populations

New nanoparticle-delivered COVID-19 vaccine candidate shows efficacy in ferret model

Ethnic minorities have less access to COVID-19 vaccines, finds study

Successful SARS-CoV-2 vaccination hinges on non-pharmaceutical interventions and vaccine deployment strategies

Moderna vaccine reduces viral spread by at least 60 percent, finds study

Scientists establish infection models for SARS-CoV-2 UK & South African variants

Enduring antibody response observed after natural immunity and first Pfizer SARS-CoV-2 vaccine shot

Tier 3 interventions needed to contain SARS-CoV-2 transmission, especially with emergence of variants

Study: Highly efficient and balanced immune response key to avoiding COVID-19 symptoms

Protein kinase inhibitors could help treat immunodeficiency in HIV patients

Single-dose of BNT162b2 vaccine may not be protective without prior SARS-CoV-2 infection

One in seven people in England show SARS-CoV-2 antibodies, finds study

Could SARS-CoV-2 antibody tests before first vaccine dose help increase coverage and protection?

Study shows how D614G variant gains upper hand over original SARS-CoV-2 virus

KHN’s ‘What the health?’: Staffing up at HHS

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

Structure of SARS-CoV-2 envelope protein-epithelial cell junction protein complex explains virulence

Why Astrazeneca and J&J’s vaccines, in use the world over, are still on hold in America

What is the impact of demographics and air quality on COVID-19 mortality?

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News